Logo

Ann Hanham

Aug 31, 2016

HTG Molecular Diagnostics has appointed Ann Hanham to its board of directors. Hanham is a founding and managing partner of BAR Capital Management. She currently serves on two other public company boards, and has served on the boards of 20 global companies, both private and public. From February 2000 to November 2013, she served as managing director and general partner of Burrill & Company.  Prior to that, Hanham held positions in clinical and regulatory affairs, and product development at various companies, including InterMune, Otsuka America Pharmaceuticals, Celtrix Pharmaceuticals, and Becton Dickinson.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.